Company research
Genvor Inc
CIK 1792941Updated Sep 29, 2026
SecurityGNVR · OTC · equity
Name history
Allure Worldwide, Inc. · through Jun 15, 2022
GNVR price & chart
Loading TradingView…
OTC:GNVR on TradingView ↗About the company
Genvor, Inc. (OTCQB: GNVR) is a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health. Powered by its proprietary BioCypher™ platform and patented peptides, Genvor is developing and intends to commercialize biological actives for crop protection and plant health alongside consumer-focused peptide solutions for recovery, performance, anti-aging, and daily wellness. Through its technology platforms and future partnerships, Genvor intends to advance a new era of natural, science-based innovation. For more information, visit www.genvor.com.
In the news
Recent filings
10-Q filing
DEF 14C filing
PRE 14C filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
3 filing
Show 4 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 5.02, 8.01, 9.01
10-Q filing
Unregistered Sales of Equity Securities · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 3.02, 5.03, 9.01
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 45,822Source | 35,580Source | 82,063Source | 315,951Source |
| Property, Plant and Equipment, NetUSD | — | 13,902Source | 15,734Source | 17,565Source |
| Current assets: | ||||
| Assets, CurrentUSD | 45,822Source | 21,678Source | 66,329Source | 298,385Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,358,204Source | 1,749,710Source | 1,787,059Source | 1,710,395Source |
| Commitments and ContingenciesUSD | — | — | — | 0Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | — | — | 0Source |
| Common Stock, Value, IssuedUSD | 29,927Source | 20,030Source | 19,062Source | 38,678Source |
| Additional Paid in CapitalUSD | 25,148,936Source | 19,168,044Source | 16,293,188Source | 14,608,815Source |
| Retained Earnings (Accumulated Deficit)USD | -26,193,306Source | -20,604,265Source | -17,719,307Source | -16,041,937Source |
| Stockholders' Equity Attributable to ParentUSD | -1,312,382Source | -1,714,130Source | -1,704,996Source | -1,394,444Source |
| Liabilities and EquityUSD | 45,822Source | 35,580Source | 82,063Source | 315,951Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 1,358,204Source | 1,749,710Source | 1,787,059Source | 1,621,174Source |
| Accounts Payable, CurrentUSD | — | — | — | 516,658Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 57,026Source | 65,665Source | — | — |
| Long-term DebtUSD | 20,000Source | — | 1,319,500Source | 1,141,221Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -5,589,000Source | -2,885,000Source | -1,707,481Source | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 4,930,000Source | 1,363,350Source | 977,235Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -555,717Source | -975,641Source | -871,734Source | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 592,575Source | 931,660Source | 619,702Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 36,858Source | -43,981Source | -252,032Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 37,231Source | 373Source | 44,354Source | 296,385Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | 356,250Source | — | — |
| DepreciationUSD | 1,376Source | 1,832Source | 1,832Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -12,528Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | 867,000Source | 5,826Source | -105,000Source | — |
| InterestExpenseNonoperatingUSD | — | — | 43,795Source | — |
| Net Income (Loss) Attributable to ParentUSD | -5,589,041Source | -2,884,958Source | -1,707,481Source | — |
| Nonoperating Income (Expense)USD | 820,810Source | -101,911Source | -268,795Source | — |
| Operating ExpensesUSD | 6,409,851Source | 2,783,047Source | 1,438,686Source | — |
| Proceeds from Issuance of Common StockUSD | 525,000Source | 911,600Source | 354,702Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 0Source |
| Operating Income (Loss)USD | -6,409,851Source | -2,783,047Source | -1,438,686Source | -3,101,904Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -5,589,041Source | -2,884,958Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -5,589,041Source | -2,884,958Source | -1,707,481Source | -3,439,524Source |
| Earnings Per Share, BasicUSD per share | — | -0.15Source | -0.07Source | -0.15Source |
| Earnings Per Share, DilutedUSD per share | -0.22Source | -0.15Source | -0.07Source | -0.15Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | 19,879,772Source | 19,545,725Source | 22,493,382Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 25,695,496Source | 19,879,772Source | 19,545,725Source | 22,493,382Source |
| Interest Expense (non-operating)USD | — | — | 43,795Source | — |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | 1,832Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | 0Source |
| Interest ExpenseUSD | 59,812Source | 17,693Source | 43,795Source | 102,792Source |
| Interest Expense, DebtUSD | 2,092Source | 17,693Source | 163,795Source | 222,792Source |
| Interest Income (Expense), NetUSD | — | — | — | -102,792Source |
| Labor and Related ExpenseUSD | — | — | 171,856Source | 390,000Source |
| Marketing and Advertising ExpenseUSD | 4,458Source | 84,183Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -3,439,524Source |
| Nonoperating Income (Expense)USD | 820,810Source | -101,911Source | -268,795Source | -337,620Source |
| Operating ExpensesUSD | 6,409,851Source | 2,783,047Source | 1,438,686Source | 3,101,904Source |
| Other ExpensesUSD | — | 16,832Source | — | — |
| Other General and Administrative ExpenseUSD | — | — | — | 171,023Source |
| Research and Development ExpenseUSD | 455,901Source | 240,263Source | 0Source | 226,448Source |
Filing attachments
ex99_1.htm · 8-K · 2026-05-21
EX-99.1 4 ex99_1.htm Exhibit 99.1 Genvor Appoints Donald Kalkofen as Chief Financial Officer Seasoned biotech CFO brings 20+ years of public company finance leadership and IPO experience to support Genvor’s dual-market growth strategy Woodland, CA - May 21, 2026 - Genvor, Inc. (OTCQB: GNVR) (“Genvor”), a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health, today announced the appointment of Donald Kalkof…
Read attachment ↗